Literature DB >> 23055343

Aberrant promoter methylation of the RASSF1A and APC genes in epithelial ovarian carcinoma development.

Rahul Bhagat1, Shilpa Chadaga, C S Premalata, G Ramesh, C Ramesh, V R Pallavi, Lakshmi Krishnamoorthy.   

Abstract

PURPOSE: Tumor suppressor gene (TSG) silencing through promoter hypermethylation plays an important role in cancer development. The aim of this study was to assess the extent of methylation of the RASSF1A and APC TSG promoters in ovarian epithelial adenomas, low malignant potential tumours and carcinomas in order to reveal a role for epigenetic TSG silencing in the development of these ovarian malignancies.
METHOD: The promoter methylation status of the RASSF1A and APC genes was assessed in 19 benign cystadenomas, 14 low malignant potential (LMP) tumours, and 86 carcinomas using methylation specific PCR (MSP).
RESULTS: The methylation frequencies of the RASSF1A and APC gene promoters in benign cystadenomas were found to be 37 % and 16 %, respectively. The LMP tumours exhibited RASSF1A and APC gene promoter methylation frequencies of 50 % and 28 %, respectively, whereas the carcinomas exhibited methylation frequencies of 58 % and 29 %, respectively. Methylation of either the RASSF1A or the APC gene promoter was encountered in 58 % of the invasive carcinomas.
CONCLUSION: The observed aberrant methylation frequencies of the RASSF1A and APC gene promoters indicate that an accumulation of epigenetic events at these specific TSG promoters may be associated with the malignant transformation of benign cystadenomas and LMP tumours to carcinomas.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23055343     DOI: 10.1007/s13402-012-0106-4

Source DB:  PubMed          Journal:  Cell Oncol (Dordr)        ISSN: 2211-3428            Impact factor:   6.730


  34 in total

1.  Hypermethylation of the CpG island of the RASSF1A gene in ovarian and renal cell carcinomas.

Authors:  J H Yoon; R Dammann; G P Pfeifer
Journal:  Int J Cancer       Date:  2001-10-15       Impact factor: 7.396

Review 2.  Cytosine methylation and human cancer.

Authors:  P M Warnecke; T H Bestor
Journal:  Curr Opin Oncol       Date:  2000-01       Impact factor: 3.645

3.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

4.  Aberrant methylation of RARbeta2 and APC genes in voided urine as molecular markers for early detection of bilharzial and nonbilharzial bladder cancer.

Authors:  Sanaa Eissa; Menha Swellam; Inas M El-Khouly; Samar K Kassim; Hanan Shehata; Amal Mansour; Mohamed Esmat; Ahmed Ibrahim Nossier; Mohamed A Hamdy; Nahla M Awad; Omar El-Ahmady
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-06-15       Impact factor: 4.254

5.  Apoptosis and APC in colorectal tumorigenesis.

Authors:  P J Morin; B Vogelstein; K W Kinzler
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-23       Impact factor: 11.205

Review 6.  The epigenomics of cancer.

Authors:  Peter A Jones; Stephen B Baylin
Journal:  Cell       Date:  2007-02-23       Impact factor: 41.582

7.  APC mutations occur early during colorectal tumorigenesis.

Authors:  S M Powell; N Zilz; Y Beazer-Barclay; T M Bryan; S R Hamilton; S N Thibodeau; B Vogelstein; K W Kinzler
Journal:  Nature       Date:  1992-09-17       Impact factor: 49.962

8.  Ubiquitous aberrant RASSF1A promoter methylation in childhood neoplasia.

Authors:  Ivy H N Wong; Jacqueline Chan; Joyce Wong; Paul K H Tam
Journal:  Clin Cancer Res       Date:  2004-02-01       Impact factor: 12.531

9.  Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients.

Authors:  Sofia Honorio; Angelo Agathanggelou; Marcus Schuermann; Wulf Pankow; Paolo Viacava; Eamonn R Maher; Farida Latif
Journal:  Oncogene       Date:  2003-01-09       Impact factor: 9.867

10.  RASSF1A and the Taxol Response in Ovarian Cancer.

Authors:  Susannah Kassler; Howard Donninger; Michael J Birrer; Geoffrey J Clark
Journal:  Mol Biol Int       Date:  2012-04-03
View more
  14 in total

Review 1.  Emerging diagnostic, prognostic and therapeutic biomarkers for ovarian cancer.

Authors:  Khalid El Bairi; Abdul Hafeez Kandhro; Adel Gouri; Wafaa Mahfoud; Noureddine Louanjli; Brahim Saadani; Said Afqir; Mariam Amrani
Journal:  Cell Oncol (Dordr)       Date:  2016-12-15       Impact factor: 6.730

2.  Genome-wide DNA methylation profiles in progression to in situ and invasive carcinoma of the breast with impact on gene transcription and prognosis.

Authors:  Thomas Fleischer; Arnoldo Frigessi; Kevin C Johnson; Hege Edvardsen; Nizar Touleimat; Jovana Klajic; Margit Lh Riis; Vilde D Haakensen; Fredrik Wärnberg; Bjørn Naume; Aslaug Helland; Anne-Lise Børresen-Dale; Jörg Tost; Brock C Christensen; Vessela N Kristensen
Journal:  Genome Biol       Date:  2014-08-22       Impact factor: 13.583

3.  Integration and bioinformatics analysis of DNA-methylated genes associated with drug resistance in ovarian cancer.

Authors:  Bingbing Yan; Fuqiang Yin; Q I Wang; Wei Zhang; L I Li
Journal:  Oncol Lett       Date:  2016-05-18       Impact factor: 2.967

4.  Epigenetic alteration of p16 and retinoic acid receptor beta genes in the development of epithelial ovarian carcinoma.

Authors:  Rahul Bhagat; Sandeep Sriram Kumar; Shilpa Vaderhobli; Chennagiri S Premalata; Venkateshaiah Reddihalli Pallavi; Gawari Ramesh; Lakshmi Krishnamoorthy
Journal:  Tumour Biol       Date:  2014-06-10

Review 5.  APC Promoter Methylation in Gastrointestinal Cancer.

Authors:  Lila Zhu; Xinyu Li; Ying Yuan; Caixia Dong; Mengyuan Yang
Journal:  Front Oncol       Date:  2021-04-23       Impact factor: 6.244

6.  Association between RASSF1A promoter methylation and ovarian cancer: a meta-analysis.

Authors:  Hao Shi; Ya Li; Xiaozhong Wang; Cheng Lu; Lilan Yang; Changmei Gu; Jiaqiang Xiong; Yangxin Huang; Shixuan Wang; Meixia Lu
Journal:  PLoS One       Date:  2013-10-08       Impact factor: 3.240

7.  Promoter hypermethylation of tumor suppressor genes correlates with tumor grade and invasiveness in patients with urothelial bladder cancer.

Authors:  Shumaila M Bilgrami; Sohail A Qureshi; Shahid Pervez; Farhat Abbas
Journal:  Springerplus       Date:  2014-04-05

Review 8.  Tumor suppressor genes and their underlying interactions in paclitaxel resistance in cancer therapy.

Authors:  Jia-Hui Xu; Shi-Lian Hu; Guo-Dong Shen; Gan Shen
Journal:  Cancer Cell Int       Date:  2016-02-20       Impact factor: 5.722

Review 9.  Targeting Wnt Signaling in Endometrial Cancer.

Authors:  Iram Fatima; Susmita Barman; Rajani Rai; Kristina W W Thiel; Vishal Chandra
Journal:  Cancers (Basel)       Date:  2021-05-13       Impact factor: 6.639

10.  Loss of RASSF1A expression in colorectal cancer and its association with K-ras status.

Authors:  Dan Cao; Ye Chen; Yuan Tang; Xing-Chen Peng; Hang Dong; Long-Hao Li; Ke Cheng; Jun Ge; Ji-Yan Liu
Journal:  Biomed Res Int       Date:  2013-06-22       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.